Regeneron Pharmaceuticals, Inc. (REGN)
938.17
+14.83
(+1.61%)
USD |
NASDAQ |
Nov 20, 10:00
Regeneron Pharmaceuticals Cash from Operations (Quarterly) : 1.783B for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.783B |
| June 30, 2026 | 813.00M |
| March 31, 2026 | 1.079B |
| December 31, 2025 | 1.171B |
| September 30, 2025 | 1.619B |
| June 30, 2025 | 1.144B |
| March 31, 2025 | 1.045B |
| December 31, 2024 | 1.263B |
| September 30, 2024 | 1.291B |
| June 30, 2024 | 354.00M |
| March 31, 2024 | 1.512B |
| December 31, 2023 | 1.090B |
| September 30, 2023 | 1.114B |
| June 30, 2023 | 1.022B |
| March 31, 2023 | 1.368B |
| December 31, 2022 | 1.720B |
| September 30, 2022 | 628.90M |
| June 30, 2022 | 564.40M |
| March 31, 2022 | 2.102B |
| December 31, 2021 | 2.372B |
| September 30, 2021 | 3.414B |
| June 30, 2021 | 626.70M |
| March 31, 2021 | 668.50M |
| December 31, 2020 | 1.231B |
| September 30, 2020 | -254.30M |
| Date | Value |
|---|---|
| June 30, 2020 | 943.40M |
| March 31, 2020 | 698.00M |
| December 31, 2019 | 787.40M |
| September 30, 2019 | 557.30M |
| June 30, 2019 | 188.30M |
| March 31, 2019 | 897.00M |
| December 31, 2018 | 728.83M |
| September 30, 2018 | 452.96M |
| June 30, 2018 | 394.56M |
| March 31, 2018 | 618.74M |
| December 31, 2017 | 566.95M |
| September 30, 2017 | 414.83M |
| June 30, 2017 | -30.57M |
| March 31, 2017 | 355.90M |
| December 31, 2016 | 377.88M |
| September 30, 2016 | 651.03M |
| June 30, 2016 | 399.50M |
| March 31, 2016 | 44.99M |
| December 31, 2015 | 281.82M |
| September 30, 2015 | 892.85M |
| June 30, 2015 | 243.61M |
| March 31, 2015 | -87.50M |
| December 31, 2014 | 198.28M |
| September 30, 2014 | 163.56M |
| June 30, 2014 | 327.79M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 5.035B |
| AbbVie, Inc. | 7.606B |
| Vertex Pharmaceuticals, Inc. | 643.10M |
| Amgen, Inc. | 4.241B |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -288.10M |
| Cash from Financing (Quarterly) | -290.20M |
| Free Cash Flow | 3.628B |
| Free Cash Flow Per Share (Quarterly) | 13.51 |
| Free Cash Flow to Equity (Quarterly) | 1.426B |
| Free Cash Flow to Firm (Quarterly) | 1.436B |
| Free Cash Flow Yield | 3.74% |